About this trial
This trial is a prospective single arm intervention study, conducting clinical research on marketed drugs. Adverse drug reactions are controllable and the risk is low, with an estimated total of 40 cases. The main objective is to evaluate the safety and efficacy of teniposide combined with cisplatin in the treatment of newly diagnosed central malignant germ cell tumors, and to conduct drug monitoring on subjects to explore potential biomarkers for predicting therapeutic efficacy. It is expected to ultimately achieve the goal of prolonging the overall survival of patients, while providing more guidance for the screening of the best treatment population and biological predictive markers.
Eligibility criteria
Qualifiers
Must have at least one measurable lesion defined by RANO criteria
The initial diagnosis has been confirmed as central malignant germ cell tumor
Expected survival period ≥ 6 months
Absolute neutrophil ≥1.0×10^9/L; Platelet ≥100.0×10^9/L
Disqualifiers
Patients undergoing any other anti-cancer experimental treatment
Individuals with a history of severe allergies or allergies to any component of the drugs in the past
Previous or concurrent active cardiovascular diseases with clinical significance, including congenital heart disease or pericardial disease, history of heart failure, myocardial infarction, coronary heart disease, heart valve disease, cardiomyopathy, and arrhythmia
Patients with Magnetic Resonance Imaging contraindications
Trial design
Treatments tested in this trial
- Teniposide Injection
Treatment groups
Sponsors and collaborators
Chengcheng Guo
Lead sponsor
Sun Yat-sen University
Sponsor institution